Elena Alifanova
Research Scientist
Elena Alifanova
Elena Alifanova has been a Research Scientist at Tioga Research since its founding in 2011 and has over ten years of experience in biochemical laboratory studies and formulation development. During her tenure at Tioga Research, Elena has designed, managed, and performed Standard Operation Procedures (“SOP”s) for a variety of advanced formulation development, stability and solubility studies for topical and transdermal drug delivery using Tioga Research HTE platforms, Franz diffusion cells, flow-through permeation cells, radiolabeling, and robotic metrology for identifying high-performing formulations. Prior to launch of Tioga Research, Elena spent over five years as a Research Technologist at Nuvo Research U.S. where she was responsible for high throughput formulation screening campaigns, permeation measurements and ELISA assays; she also developed SOPs and qualification reports, and contributed to the development of several formulation innovations, such as PENNSAID 2% for treatment of osteoarthritis of the knee. Prior to joining Nuvo Research, Elena held positions as a Research and Laboratory Associate at research institutions in Russia where she conducted experimental studies of blood samples using erythrocytapheresis. Elena holds a M.S. in Biochemistry from Nizhny Novgorod State University, Russia.
CSO
Edward Kisak
Edward T. Kisak has served as CSO of Tioga Research since its founding. He has over twenty years of experience in topical formulation development, having served in both managerial and lead scientist roles. Ed has a PhD in Chemical Engineering from the University of California, Santa Barbara where his doctoral research focused on developing “vesosomes” – a multiplexed liposomal structure containing liposomes nested within other liposomes for advanced drug delivery therapies. This doctoral research was later pursued by Advanced Encapsulation – a start-up company co-founded by Ed to improve and develop the vesosome technology. Ed also served as consultant to Sinus Pharmaceuticals and reformulated their lead tobramycin sinusitis formulation, which later went on to clinical trials. After joining fqubed (later acquired by Nuvo Research, CA:NRI) in 2005, Ed acted as Director of Research, and was responsible for laboratory operations and for managing formulation innovation and skin delivery screening campaigns. During this tenure, Ed acted as the lead formulation scientist on developing PENNSAID® 2% (currently approved in the US for the treatment of osteoarthritis) along with other formulations in Nuvo’s pipeline. Additionally, he was the prime driving force behind the development, optimization and production-mode use of Tioga Research’s HTE platforms, including INSIGHT™, STORM™, SPATE™, SPLASH™, TORNADO™, MONSOON™ and SKIVER™.
He is an inventor on more than 30 issued and pending patents, including that claiming the PENNSAID® 2% formulation.
Doctor
Hello, i’m guy hawkins
There are many variations of passages of Lorem Ipsum avagtilable, but the majority have suffered alteration in some form, by injected hudfdfmour, or randomised words which don't look
The generated lorem ipsum is therfore always free from repetition, injected humour, or
- Experience:23 Years
- Email: demo@gmail.com
- Phone: +(684) 555-0102
Digital marketing
SEO
Certificates & education
There are many variations of passages of Lorem Ipsum avagtilable, but the majority have suffered alteration in some form
CONTACT US
